theralizumab
Sign in to saveAlso known as TGN1412, CD28-SuperMAB, TAB08
Theralizumab (also known as TGN1412, CD28-SuperMAB, and TAB08) is an immunomodulatory drug developed by immunologist of the University of Würzburg. It was withdrawn from development after inducing severe inflammatory reactions as well as chronic organ failure in the first-in-human study by Parexel in London in March 2006. The developing company, TeGenero Immuno Therapeutics (), a spin-off of the University of Würzburg around immunologist Thomas Hünig, co-founder and chief scientific officer (CSO) Thomas Hanke and chief executive officer (CEO) Benedikte Hatz went bankrupt later that year. The c
In the Vinony graph
Vinony's link graph records 188 inbound references to theralizumab, and connects out to crab-eating macaque, in vitro experiment and intravenous infusion and defusion.
It sits within the topics 2006 in London, Abandoned drugs and Chemical pages without DrugBank identifier.
Vinony links it to 12 Wikipedia language editions.
~18 min read
Encyclopedic overview
10 sectionsContents
- Production
- Pharmacology
- Mechanism of action
- History
- Investigations
- Follow up publications
- Controversies
- See also
- References
- External links
Theralizumab (also known as TGN1412, CD28-SuperMAB, and TAB08) is an immunomodulatory drug developed by immunologist of the University of Würzburg. It was withdrawn from development after inducing severe inflammatory reactions as well as chronic organ failure in the first-in-human study by Parexel in London in March 2006. The developing company, TeGenero Immuno Therapeutics (), a spin-off of the University of Würzburg around immunologist Thomas Hünig, co-founder and chief scientific officer (CSO) Thomas Hanke and chief executive officer (CEO) Benedikte Hatz went bankrupt later that year. The commercial rights were then acquired by a Russian startup, TheraMAB. The drug was renamed TAB08. Phase I and II clinical trials have been completed for arthritis and clinical trials have been initiated for cancer.
Originally intended for the treatment of B cell chronic lymphocytic leukemia (B-CLL) and rheumatoid arthritis, TGN1412 is a humanised monoclonal antibody that not only binds to, but is a strong agonist for, the CD28 receptor of the immune system's T cells. CD28 is the co-receptor for the T cell receptor; it binds to receptors on the interacting partner in the reaction through one of its ligands (B7 family).
Excerpted from Wikipedia’s “theralizumab” article, available under the CC BY-SA 4.0 licence.